Noam Frey
Corporate Officer/Principal presso SUMMIT THERAPEUTICS INC.
Profilo
Noam Frey is currently working as the Senior VP-Global Medical Affairs at Summit Therapeutics, Inc. Prior to this, he held the position of Vice President-Medical Affairs at Amryt Pharma Holdings Ltd.
from 2022 to 2023.
He also worked as the Vice President-Medical Affairs at InterMune, Inc. from 2013 to 2015.
Dr. Frey completed his MBA from the University of Washington and holds a doctorate degree from Tel-Aviv University.
Posizioni attive di Noam Frey
| Società | Posizione | Inizio |
|---|---|---|
| SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 01/09/2023 |
Precedenti posizioni note di Noam Frey
| Società | Posizione | Fine |
|---|---|---|
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 01/04/2023 |
| INTERMUNE INC | Direttore Tecnico/Scientifico/R&S | 01/02/2015 |
Formazione di Noam Frey
| Tel-Aviv University | Doctorate Degree |
| University of Washington | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SUMMIT THERAPEUTICS INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Noam Frey
